Anbio Biotechnology shares surge 13.67% intraday after announcing Chikungunya rapid test and 15-minute PCR system to address global outbreaks.

Anbio Biotechnology (NNNN) surged 13.67% intraday following announcements of its diagnostic innovations. The company highlighted its veterinary diagnostic portfolio at the WSAVA 2025 conference and launched a Chikungunya rapid test alongside a 15-minute ultra-fast PCR system. These developments underscore Anbio’s expansion in global diagnostic solutions, aligning with increased demand for rapid testing technologies. The timing of these product launches and conference participation likely drove immediate investor optimism, contributing to the sharp intraday price increase.